Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review)

Oncology Reports

Volumn 9, Issue 4, 2002, Pages 683-688

  Van Vulpen, Marco ^a   Kal, Henk B ^a   Taphoorn, Martin J B ^a   El Sharouni, Sherif Y ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Blood brain barrier; Chemotherapy; Irradiation; Mannitol; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN; BRAIN TUMOR; CAPILLARY PERMEABILITY; HUMAN; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; REVIEW; TIME; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; COMBINED MODALITY THERAPY; HUMANS; TIME FACTORS;

EID: 0036632353     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.4.683     Document Type: Review

References (64)

1. Rubin LL and Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 22: 11-28, 1999. (Pubitemid 29144879)
2. Habgood MD, Begley DJ and Abbott NJ: Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 20: 231-253, 2000. (Pubitemid 30091458)
3. De Boer AG and Breimer DD: The blood-brain barrier: clinical implications for drug delivery to the brain. JR Coll Physicians Lond 28: 502-506, 1994. (Pubitemid 24373680)
4. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
5. Larsson B: Blood vessel changes following local irradiation of the brain with high energy protons. Acta Soc Med Ups 65: 61-64, 1960.
6. Blasberg RG, Groothuis D and Molnar P: A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models. In: Pathophysiology of the Blood-Brain Barrier. Johansson BB and Widner COH (eds). Elsevier, New York, pp 197-220, 1990. (Pubitemid 20353019)
7. Qin DX, Zheng R, Tang J, Li JX and Hu Y: Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 19: 1507-1510, 1990.
8. Brandes AA and Fiorentino MV: The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 14: 551-559, 1996. (Pubitemid 26423517)
9. Balis FM and Poplack DG: Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 11: 74-86, 1989. (Pubitemid 19073291)
10. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R and Dana B: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580-1590, 1991.
11. Morikawa N, Mori T, Abe T, Kawashima H, Takeyama M and Hori S: Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy. Biol Pharm Bull 22: 428-431, 1999. (Pubitemid 29219991)
12. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH and Neuwelt EA: The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sei Am 4: 110-124, 1998. (Pubitemid 29090715)
13. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL and Neuwelt EA: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 1: 637-647, 2000. (Pubitemid 30056941)
14. Doolittle ND, Petrillo A, Bell S, Cummings P and Eriksen S: Blood-brain barrrier disruption for the treatment of malignant brain tumors: The National Program. J Neurosci Nurs 30: 81-90, 1998.
15. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR and Neuwelt EA: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46: 51-60, 2000.
16. Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH and Boddy AV: Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumors. Cancer Chemother Pharmacol 45: 284-290, 2000. (Pubitemid 30151521)
17. Clougheshy TF, Black KL, Gobin YP, Farahani K, Nelson G, Villablanca P, Kabbinavar F, Vineula F and Wortel CH: Intraarterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 44: 270-278, 1999.
18. Jarden JO, Dhawan V, Poltorak A, Posner JB and Rottenberg DA: Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb: the effect of dexamethasone and whole brain radiation therapy. Ann Neurol 18: 636-646, 1985. (Pubitemid 16085157)
19. Stephani U, Rating D, Korinthenberg R, Siemes H, Riehm H and Hanefeld F: Radiation related disturbance of blood/brain barrier during therapy of acute lymphoblastic leucaemia. Lancet 2: 1036-1037, 1983.
20. Morantz RA, Kimler BF, Vats TS and Henderson SD: Bleomycin and brain tumors: a review. J Neurooncol 1: 249-255, 1983.
21. Livrea P, Trojano M, Simone IL, Zimatore GB, Logroscino GC, Pisicchio L, Lojacono G, Colella R and Ceci A: Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 231: 336-339, 1985. (Pubitemid 15197063)
22. Ludwig R: Effect of cranial irradiation on the bloodcerebrospinal fluid and blood-brain barrier. Klin Padiatr 199: 233-238, 1987.
23. Tellkamp H and Kohler K: Dynamic CT in the follow-up assessment of irradiated intracranial tumors. Digitale Bilddiagn 7: 183-186, 1987. (Pubitemid 18040872)
24. Groothuis DR, Wright DC and Ostertag CB: The effect of 125I interstitial radiotherapy on blood-brain barrier function in normal canine brain. J Neurosurg 67: 895-902, 1987. (Pubitemid 18005537)
25. D'Avella D, Cicciarelllo R, Albiero F, Mesiti M, Gagliardi ME, Russi E, d'Aquino A, Tomasello F and d'Aquino S: Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery 30: 30-34, 1992.
26. D'Avella D, Cicciarelllo R, Angileri FF, Lucerna S, La Toirre D and Tomassello F: Radiation-induced blood brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl Wien 71: 282-284, 1998. (Pubitemid 128444421)
27. Krueck WG, Schmiedl UP, Maravilla KR, Spence AM, Starr FL and Kenney J: MR assessment of radiation-induced blood-brain barrier permeability changes in rat glioma model. Am J Neuroradiol 15: 625-632, 1994. (Pubitemid 24128823)
28. Nakata H, Yoshimine T, Murasawa A, Kumura E, Harada K, Ushio Y and Hayakawa T: Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats. Acta Neurochir Wien 136: 82-86, 1995.
29. Tourtellotte WW, Potvin AR, Baumheffner RW, Potvin JH, Ma BI, Syndulko K and Petrovich Z: Multiple sclerosis de novo CNS IgG synthesis. Effect of CNS irradiation. Arch Neurol 37: 620-624, 1980. (Pubitemid 10018486)
30. Groothuis DR and Mikhael MA: Focal cerebral vasculitis associated with circulating immune complexes and brain irradiation. Ann Neurol 19: 590-592, 1986. (Pubitemid 16085194)
31. Hatanaka H, Moritani M and Camillo M: Possible alteration of the blood-brain barrier by boron-neutron capture therapy. Acta Oncol 30: 375-378, 1991.
32. Dorn RV, Spickard JH and Griebenow ML: The effects of ionizing radiation and dexamethasone on the blood-brain barrier and blood-tumor-barrier: implications for boron neutron capture therapy of brain tumors. Strahlenther Onkol 165: 219-221, 1989. (Pubitemid 19073431)
33. Storm AJ, van der Kogel AJ and Nooter K: Effect of X-irradiation on the pharmacokinetics of methotrexate in rats: alteration of the blood-brain barrier. Eur J Cancer Clin Oncol 21:759-764, 1985. (Pubitemid 15119338)
34. Qin D, Ma J, Xiao J and Tang Z: Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol 20: 263-265, 1997. (Pubitemid 27221046)
35. Qin D, Ou G, Mo H, Song Y, Kang G, Hu Y and Gu X: Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys 5: 959-962, 2001. (Pubitemid 33026426)
36. Crossen JR, Goldman DL, Dahlborg SA and Neuwelt EA: Neuropsychologic assessment outcomes of non-acquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 30: 23-29, 1992.
37. Rapaport SI: Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 20: 217-230, 2000.
38. Gregor A, Lind M, Newman H, Grant R, Hadley DM, Barton T and Osborn C: Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J Neurooncol 44: 137-145, 1999.
39. Remsen LG, Marquez C, Garcia R, Thrun LA and Neuwelt EA: Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. Int J Radiat Oncol Biol Phys 15: 1045-1049,2001. (Pubitemid 33026436)
40. Barth RF, Yang W, Rotaru JH, Moeschberger ML, Boesel CP, Soloway AH, Joel DD, Nawrocky MM, Ono K and Goodman JH: Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys 47: 209-218, 2000. (Pubitemid 30179697)
41. Yang W, Barth RF, Bartus RT, Rotaru JH, Moeschberger ML, Ferketich AK, Nawrocky MM, Coderre JA and Goodman JH: Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine. Neurosurgery 47: 189-197, 2000.
42. Spence AM, Graham MM, O'Gorman LA, Muzi M, Abbott GL and Lewellen TK: Regional blood-to-tissue transport in an irradiated rat glioma model. Radiat Res 111: 225-236, 1987. (Pubitemid 17156947)
43. Chan YL, Leung SF, King AD, Choi PH and Metreweli C: Late radiation injury to the temporal lobes: morphologic evaluation at MR imaging. Radiology 213: 800-807, 1999.
44. DeAngelis LM, Burger PC, Green SB and Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44: 691-695, 1998. (Pubitemid 28477860)
45. Taphoorn MJB, Klein Schiphorst A, Snoek FJ, Lindeboom J, Wolbers JG, Karim ABMF, Huijgens PC and Heimans JJ: Cognitive functions and quality of life in patients with low-grade glioma: the impact of radiotherapy. Ann Neurol 36: 48-54, 1994. (Pubitemid 24205823)
46. Liengswangwong V and Bonner JA: Prophylactic cranial irradiation in limited stage small cell lung cancer. Cancer 75: 1302-1309, 1995.
47. Arriagada R, le Chevalier T, Borie F, Riviere A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M and Benhamou S: Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. J Natl Cancer Inst 87: 183-190, 1995.
48. Van Oosterhout AGM, Boon PJ, Houx PJ, ten Velde GPM and Twijnstra A: Follow-up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 31: 911-914, 1995.
49. Van Oosterhout AGM, Ganzevles PGJ, Wilmink JT, de Geus BWJ, van Vonderen RGMW and Twijnstra A: Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 34: 1037-1044, 1996. (Pubitemid 26105441)
50. Emami B, Lyman J, Brown A, Coia L, Goitien M, Munzenrider JE, Shank B, Solin LJ and Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109-122, 1991.
51. Evans RG, Kimler BF, Morantz RA and Batnitzky S: Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26: 649-652, 1993. (Pubitemid 23220164)
52. Recht L, Fram RJ, Strauss G, Fitzgerald TJ, Liepman M, Lew R, Kadish S, Sherman D, Wilson J and Greenberger J: Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial. Am J Clin Oncol 13: 125-131, 1990. (Pubitemid 20170264)
53. Madajewicz S, Chowhan N, Tfayli A, Roque C, Meek A, Davis R, Wolf W, Cabahug C, Roche P, Manzione J, Iliya A, Shady M, Hentschel P, Atkins H and Braun A: Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer 88: 2350-2356, 2000. (Pubitemid 30247136)
54. Crossen JR, Garwood D, Glatstein E and Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627-642, 1994. (Pubitemid 24079908)
55. Jarden JO: Pathophysiologic aspects of malignant brain tumors studied with positron emission tomography. Acta Neurol Scand (Suppl. 156): 1-35, 1994.
56. DeAngelis LM, Delattre JY and Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurol 39: 789-796, 1989. (Pubitemid 19150153)
57. Bunn PA and Kelly K: Prophylactic cranial irradiation for patients with small cell lung cancer. J Natl Cancer Inst 87: 161-162, 1995.
58. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krish RE and Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993. (Pubitemid 23133591)
59. Hosli P, Sappino AP, de Tribolet N and Dietrich PY: Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol 9: 589-600, 1998. (Pubitemid 28318190)
60. Friedman HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 27: 35-40, 2000.
61. Stupp R and Newlands E: New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol 28 (Suppl. 13): 19-23,2001. (Pubitemid 32879942)
62. Auperin A, Amagada R, Pignon JP, le Pechoux C, Gregor A, Stephens RJ, Kristjansen PEG, Johnson BE, Ueoka H, Wagner H and Aisner J: Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 341: 476-484, 1999. (Pubitemid 29372887)
63. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssen PE and Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43: 795-803, 1999. (Pubitemid 29152652)
64. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA and Renschler MF: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19: 2074-2083, 2001. (Pubitemid 32702553)